Abstract 323P
Background
Tumor mutation burden (TMB) may predict immune checkpoint inhibitor (ICI) response. TMB calculation included all nonsynonymous somatic mutations, but not all mutations were favorable and the efficient of TMB is attenuated by including adverse mutations. Moreover, no universal cutoff value of high TMB hindered its application in practice.
Methods
Tumor mutation score (TMS), defined as number of genes with nonsynonymous somatic mutations, was compared with TMB in 10,336 cancer patients from MSK-IMPACT cohort. TMS55, TMS of 55 favorable prognosis genes and TMB were calculated and compared in 1,661 advanced cancer patients treated with ICI and 3,840 matching non-ICI patients of ten major cancer types.
Results
TMS55 was significantly associated with TMB. In 1,661 ICI patients, high TMS55 (TMS55>5) was more robust than high TMB (highest 20% in each histology) in predicting better overall survival. Separately, TMS55 was significantly associated with improved survival in more tumor types than TMB with smaller hazard ratio values, especially in non-small cell lung cancer, melanoma, bladder cancer and colorectal cancer. Conversely, high TMS55 and TMB predicted worse overall survival in 3,840 non-ICI patients.
Conclusions
Novel TMS55 might be better than TMB as biomarker for patients treated with ICI and customized TMS might substitute non-selective TMB as mutation-based biomarker. Easy calculation and universal cutoff value of TMS will not be affected across platforms and is more feasible in clinical, which may greatly promote its application in clinical with further validations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract